Compare PW & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | SILO |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Apparel |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.1M |
| IPO Year | 2011 | 2011 |
| Metric | PW | SILO |
|---|---|---|
| Price | $6.69 | $1.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 34.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.90 | 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,982,265.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.32 | N/A |
| 52 Week Low | $0.50 | $0.22 |
| 52 Week High | $12.92 | $7.95 |
| Indicator | PW | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 26.74 |
| Support Level | $6.46 | $1.63 |
| Resistance Level | $8.04 | $4.80 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 42.03 | 22.37 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.